MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

29.29 +0.27 (+0.93%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Beam Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results
From Beam Therapeutics
Via GlobeNewswire
News headline image
ViaSat & AST SpaceMobile Are Among Top 6 Mid Cap Stocks That Shined The Brightest Last Week (July 21-July 27): Are The Others In Your Portfolio? ↗
Top mid-cap stocks of the week: ASTS up 47.88%, GSHD up 39.86%, VSAT up 30.78%, VKTX up 29.86%, BEAM up 23.93%, CLDX up 19.72% 
Via Benzinga
News headline image
IBM Posts Upbeat Earnings, Joins ServiceNow, Helmerich & Payne, RTX, Nasdaq And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
Expert Ratings For Beam Therapeutics ↗
 
Via Benzinga
News headline image
Expert Outlook: Beam Therapeutics Through The Eyes Of 4 Analysts ↗
 
Via Benzinga
News headline image
Beam Therapeutics Stock Earns RS Rating Jump To 85 ↗
On Wednesday, Beam Therapeutics stock now clears the 80 or higher Relative Strength Rating threshold, with a jump from 65 to 85. 
Via Investor's Business Daily
News headline image
Why Is Conn’s (CONN) Stock Down 36% Today? ↗
Conn’s stock is falling on Wednesday as CONN investors react to reports of potential store closures and a bankruptcy filing. 
Via InvestorPlace
Topics Bankruptcy
News headline image
Trade of the Day: Buy Beam Therapeutics Call Options as BEAM Stock Heads to $40 ↗
Beam Therapeutics recently got a vote of confidence from a Wall Street analyst, providing fuel for further upside in BEAM stock. 
Via InvestorPlace
News headline image
Danaher Posts Upbeat Earnings, Joins Spotify, MSCI, Owens & Minor And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
3 Gene Editing Stocks Shaping the Future of Medicine ↗
Gene editing stocks offer a bold venture into biopharma's future, leveraging CRISPR technology for transformative healthcare solutions 
Via InvestorPlace
News headline image
Cathie Wood-Led Ark Invest Sells $8M In Tesla Shares Despite Bullish Autonomy Forecast ↗
 
Via Benzinga
News headline image
Beam Therapeutics Announces Transition of Chief Financial Officer
From Beam Therapeutics
Via GlobeNewswire
News headline image
The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024 ↗
Finding undervalued gene editing stocks is easy, but having the patience to stick with them is the challenge. 
Via InvestorPlace
News headline image
3 Stocks With the Potential to 10X Your Money ↗
These three top high-growth potential stocks could offer substantial growth and give your portfolio a major boost. 
Via InvestorPlace
News headline image
FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals ↗
Biotech stocks are on the verge of a comeback after a period of underperformance amid a wave of FDA approvals. 
Via InvestorPlace
News headline image
3 Stocks This Amazon-Backed AI Says Will Turn $1K into $1M by 2030 ↗
These high-risk, high-reward stocks have the potential to turn $1K into $1M by 2030, according to Amazon-backed AI Claude 3.5 Sonnet. 
Via InvestorPlace
Topics Artificial Intelligence
News headline image
You’ve Been Warned! 3 Gene Editing Stocks to Buy Now or Regret Forever. ↗
The best gene editing stocks to buy are those with strong tehnogical applications and genuine commercialization prospects. 
Via InvestorPlace
News headline image
Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics to Participate in Jefferies Global Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress
From Beam Therapeutics
Via GlobeNewswire
News headline image
Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine ↗
These biotech breakthrough stocks give investors a glimpse into medicine's future -- and massive moneymaking opportunities to boot. 
Via InvestorPlace
News headline image
Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
News headline image
BEAM Stock Earnings: Beam Therapeutics Beats EPS, Misses Revenue for Q1 2024 ↗
BEAM stock results show that Beam Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results
From Beam Therapeutics
Via GlobeNewswire
News headline image
Popular Crypto Trader Shares 2024 Predictions For These Three Altcoins ↗
Popular pseudonymous crypto analyst Altcoin Sherpa on Friday shared his insights on three altcoins: Beam (CRYPTO: BEAM), Arbitrum (CRYPTO: ARB), and Render (CRYPTO: 
Via Benzinga
News headline image
Gene Therapy Side Effects: Verve Therapeutics Halts Enrollment Of Lead Gene Therapy Trial In Patients With Bad Cholesterol ↗
Verve Therapeutics' latest update on the Heart-1 Phase 1b trial of VERVE-101. Explore VERVE-102's development and regulatory clearances for the Heart-2 clinical trial, offering hope for patients with... 
Via Benzinga
News headline image
Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
Initiation of Phase 1/2 Trial of BEAM-302 in AATD Expected in First Half of 2024 
From Beam Therapeutics
Via GlobeNewswire
News headline image
MarketBeat Week in Review – 3/4 – 3/8
The market rally continues as the February Jobs Report reignited the soft landing talk, but momentum could stall if next week's inflation readings come in hot 
Via MarketBeat
Topics Artificial Intelligence Economy
News headline image
Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments
Beam Therapeutics stock is rising as the company begins to receive significant money from the multiple licensing deals it has in place 
Via MarketBeat
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story